Everything you need to know about the trial results for a new coronavirus vaccine
In an interim analysis of a phase 3 clinical trial conducted in the UK, the vaccine has shown 89% efficacy, with 27% of participants in the trial – almost 4,000 people – older than 65. That trial suggested 95.6% efficacy against the original coronavirus and 85.6% efficacy against the more recent UK variant. Those results were based on the first 62 cases of Covid-19 identified among volunteers, with 56 cases among those given a placebo against just six in those given the vaccine. They were based on symptomatic cases of Covid, but the team says further results expected soon will shed light on whether the vaccine also has an effect on asymptomatic infections.
